Physician profile
Jason Mallin
NPI 1316083835
$3,753.96
in general payments reported to CMS, 2019-2025
34 companies · $541 in 2025
The $541 reported for 2025 was more than what 80% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $667 · 2020: $369 · 2021: $756 · 2022: $225 · 2023: $447 · 2024: $749 · 2025: $541.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,737.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,737.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $712.98 | 2021-2025 | |
| Neurocrine Biosciences, INC. | $659.47 | 2019-2025 | Ingrezza |
| Biogen, INC. | $377.44 | 2019-2023 | Vumerity |
| Novartis Pharmaceuticals Corporation | $302.61 | 2019-2025 | |
| Amgen INC. | $279.40 | 2019-2023 | Repatha, Otezla |
| E.R. Squibb & Sons, L.L.C. | $159.45 | 2020-2024 | Zeposia |
| Supernus Pharmaceuticals, INC. | $138.53 | 2019-2020 | |
| Celgene Corporation | $128.59 | 2023-2025 | Zeposia |
| Sk Life Science, INC. | $103.00 | 2023-2024 | |
| Argenx US, INC. | $101.22 | 2023-2024 | Vyvgart, Vyvgart Hytrulo |
| Genentech USA, INC. | $99.83 | 2019-2025 | Ocrevus Zunovo |
| Acadia Pharmaceuticals INC | $82.79 | 2019-2022 | |
| Lilly USA, LLC | $64.66 | 2019-2024 | Emgality |
| Janssen Biotech, INC. | $61.94 | 2025 | |
| Pfizer INC. | $56.42 | 2021-2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $48.00 | 2023-2024 | Prolastin-C Liquid |
| Alexion Pharmaceuticals, INC. | $35.17 | 2020-2023 | Ultomiris |
| Csl Behring | $32.39 | 2023 | Hizentra |
| Arbor Pharmaceuticals, INC. | $31.03 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $29.56 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $27.73 | 2021-2024 | Verquvo |
| Janssen Pharmaceuticals, INC | $26.80 | 2022 | |
| Tanabe Pharma America, INC. | $25.54 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $20.07 | 2022 | |
| Abbott Laboratories | $17.84 | 2024 | Infinity |
| Averitas Pharma INC. | $17.02 | 2023 | Qutenza |
| Lundbeck LLC | $16.92 | 2020 | |
| Tg Therapeutics, INC. | $15.16 | 2025 | |
| Vifor Pharma, INC. | $14.88 | 2022 | |
| Fresenius USA Marketing, INC. | $14.73 | 2025 | Velphoro |
| Philips North America LLC | $14.06 | 2020 | |
| Amneal Pharmaceuticals LLC | $13.58 | 2021 | |
| Allergan, INC. | $12.99 | 2020 | |
| Impel Pharmaceuticals INC. | $12.16 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Mallin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.